My watch list  

8 Newest Publications about the topic velcade


You can refine your search further. Select from the filter options on the left to narrow down your results.

Nuclear Translocation of B-Cell-Specific Transcription Factor, BACH2, Modulates ROS Mediated Cytotoxic Responses in Mantle Cell Lymphoma

02-Aug-2013 | Zheng Chen et al., PLoS ONE, 2013

by Zheng Chen, Eric F. Pittman, Jorge Romaguera, Luis Fayad, Michael Wang, Sattva S. Neelapu, Peter Mclaughlin, Larry Kwak, Nami McCarty BACH2, a B-cell specific transcription factor, plays a critical role in oxidative stress-mediated apoptosis. Bortezomib (VelcadeTM) is widely used to treat ...


Expression of Vascular Endothelial Growth Factor Receptors VEGFR1 in Cultured Multiple Myeloma Cells: Correlation with Immunophenotype and Drug Resistance

01-Nov-2012 | N. N. Kalitin, M. N. Kostyukova, E. S. Kakpakova, N. N. Tupitsyn, A. F. Karamysheva, Bulletin of Experimental Biology and Medicine, 2012

We studied the expression of genes encoding vascular endothelial growth factors VEGF-A, VEGF-C, VEGF-D and their receptors in cell cultures of human multiple myeloma IM9, RPMI 1640, RPMI 8226. The studied cells did not differ by the expression of growth factors. Expression of VEGFR1 receptor was ...


Molecular Mechanisms of Bortezomib Resistant Adenocarcinoma Cells

22-Dec-2011 | Erika Suzuki et al., PLoS ONE, 2011

by Erika Suzuki, Susan Demo, Edgar Deu, Jonathan Keats, Shirin Arastu-Kapur, P. Leif Bergsagel, Mark K. Bennett, Christopher J. Kirk Bortezomib (Velcade™) is a reversible proteasome inhibitor that is approved for the treatment of multiple myeloma (MM). Despite its demonstrated clinical ...


Targeting the extrinsic apoptosis signaling pathway for cancer therapy

05-Apr-2011 | Thomas J. Sayers, Cancer Immunology, Immunotherapy, 2011

The extrinsic apoptosis pathway is triggered by the binding of death ligands of the tumor necrosis factor (TNF) family to their appropriate death receptors (DRs) on the cell surface. One TNF family member, TNF-related apoptosis-inducing ligand (TRAIL or Apo2L), seems to preferentially cause ...


Analysis of Two Commercially Available Bortezomib Products: Differences in Assay of Active Agent and Impurity Profile

01-Apr-2011 | Stephen R. Byrn, Patrick A. Tishmack, Mark J. Milton, Helgi van de Velde, AAPS PharmSciTech, 2011

The analytical properties of two commercially available bortezomib products (VELCADE® and Bortenat) were compared using nuclear magnetic resonance, mass spectrometry, high-performance liquid chromatography, and gas chromatography. The data showed differences between the two products. Based on ...


A cell-based screen for inhibitors of protein folding and degradation

18-Aug-2010 | Frank Boschelli, Jennifer M. Golas, Roseann Petersen, Vincent Lau, Lei Chen, Diane Tkach, Qiang Zhao, Dave S. Fruhli ..., Cell Stress and Chaperones, 2010

Cancer cells are exposed to external and internal stresses by virtue of their unrestrained growth, hostile microenvironment, and increased mutation rate. These stresses impose a burden on protein folding and degradation pathways and suggest a route for therapeutic intervention in cancer. ...


Optimized combination therapy using bortezomib, TRAIL and TLR agonists in established breast tumors

10-Mar-2010 | Sujin Lee, Hideo Yagita, Thomas J. Sayers, Esteban Celis, Cancer Immunology, Immunotherapy, 2010

TNF-related apoptosis-inducing ligand (TRAIL) is a member of the TNF family of cytokines, which can induce apoptosis in various tumor cells by engaging the receptors, DR4 and DR5. Bortezomib (Velcade) is a proteasome inhibitor that has been approved for patients with multiple myeloma. There is ...


Tieg1/Klf10 is upregulated by NGF and attenuates cell cycle progression in the pheochromocytoma cell line PC12

12-Feb-2010 | Gabriele Spittau, Nicole Happel, Maik Behrendt, T. Ivo Chao, Kerstin Krieglstein, Björn Spittau, Journal of Neuroscience Research, 2010

The transcription factor Tieg1/Klf10 belongs to a family of Sp1/Klf proteins that have been shown to play important roles during development and maintenance of various tissues and cell types. Upregulation of Tieg1/Klf10 has been reported for TGF-[beta], BMP2, BMP4, ActivinA and GDNF as members of ...


Page 1 From 1
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE